New study tests 2-Year dupilumab treatment for Kids' eczema
NCT ID NCT05983068
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at how well dupilumab (Dupixent) works over two years in about 48 children aged 6 to 14 with moderate-to-severe eczema. The main goal is to see if the drug improves the skin's barrier function, measured by water loss through the skin. All participants receive dupilumab, and the study tracks safety and skin changes over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dupilumab (Dupixent)
What this could lead to
If successful, this could show that long-term dupilumab use improves skin barrier function in children with eczema, supporting its continued use for disease control.
What could go wrong
This is a small, open-label study with no placebo group, so results may not be definitive. Side effects like injection reactions or infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 8260001
Sheffield, S10 2TH, United Kingdom
-
NYU Langone Medical Center- Site Number : 8400004
New York, New York, 10016, United States
-
National Jewish Health Medical Center- Site Number : 8400001
Denver, Colorado, 80206, United States
-
SSM Health Saint Louis University Hospital- Site Number : 8400006
St Louis, Missouri, 63104, United States